Natera (NTRA) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 revenue of $439.8M, up 64% year-over-year, with ~776K tests processed and oncology test volumes up 54%.

• Gross margin improved to 62% in Q3 2024 from 45% in Q3 2023, driven by higher ASPs and cost efficiencies.

• Generated $34.5M in cash inflow, marking the third consecutive quarter of positive cash flow.

• Net loss narrowed to $31.6M ($0.26/share) in Q3 2024, compared to $109.0M ($0.95/share) in Q3 2023.

• Published groundbreaking GALAXY study data in Nature Medicine, validating Signatera's predictive value for survival in colorectal cancer.

Financial highlights

• Q3 2024 revenue reached $439.8M, a 64% increase year-over-year, with gross margin at 61.8%.

• Product revenues were $436.1M, licensing and other revenues $3.6M in Q3 2024.

• Net loss per diluted share improved to ($0.26) from ($0.95) in Q3 2023.

• Cash and investments totaled $922.3M as of September 30, 2024.

• Operating expenses rose 34% to $311.1M, mainly due to headcount, consulting, and legal costs.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $1.61B–$1.64B, gross margin expected at 58%–61%, and net cash inflow projected at $50M–$75M.

• SG&A costs expected at $775M–$825M and R&D at $375M–$400M for 2024.

• Guidance reflects continued volume growth, strong oncology contribution, and conservative ASPs.

• 2025 baseline goal is to match 2024 unit growth, with some headwinds from non-recurring women's health volume influx.